271 related articles for article (PubMed ID: 20824907)
61. Sudden significant total protein concentration change: not an analytical problem.
Dimeski G; Wood P
J Clin Lab Anal; 2011; 25(5):330-1. PubMed ID: 21919066
[No Abstract] [Full Text] [Related]
62. [A cure for multiple myeloma?].
Harousseau JL
Presse Med; 2006 Sep; 35(9 Pt 2):1288-90. PubMed ID: 16969322
[No Abstract] [Full Text] [Related]
63. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R; Cibeira MT; Uriburu C; Yantorno S; Salamero O; Bladé J; Montserrat E
Eur J Haematol; 2006 May; 76(5):405-8. PubMed ID: 16529604
[TBL] [Abstract][Full Text] [Related]
64. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
65. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
66. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Palumbo A; Mateos MV; Bringhen S; San Miguel JF
Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
[TBL] [Abstract][Full Text] [Related]
67. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Perfetti V; Palladini G; Brunetti L; Sgarella A; Brugnatelli S; Gobbi PG; Corazza GR
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):599-601. PubMed ID: 17556909
[TBL] [Abstract][Full Text] [Related]
68. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
69. An update on drug combinations for treatment of myeloma.
Srikanth M; Davies FE; Morgan GJ
Expert Opin Investig Drugs; 2008 Jan; 17(1):1-12. PubMed ID: 18095914
[TBL] [Abstract][Full Text] [Related]
70. Treatment of newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Larocca A; Bringhen S; Falco P; Di Raimondo F; Baldini L; Boccadoro M
Curr Hematol Malig Rep; 2008 Apr; 3(2):107-14. PubMed ID: 20425454
[TBL] [Abstract][Full Text] [Related]
71. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Pamukçuoğlu M; Emmez H; Tunçcan OG; Oner AY; Cırak MY; Senol E; Sucak GT
Hematology; 2014 Apr; 19(3):158-62. PubMed ID: 23906027
[TBL] [Abstract][Full Text] [Related]
72. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
[No Abstract] [Full Text] [Related]
73. The role of novel drugs in multiple myeloma.
Dimopoulos MA; Kastritis E
Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953
[No Abstract] [Full Text] [Related]
74. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
75. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
76. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
77. Current status of new drugs for the treatment of patients with multiple myeloma.
Kenealy M; Prince HM
Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
[TBL] [Abstract][Full Text] [Related]
78. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
80. European perspective on multiple myeloma treatment strategies: update following recent congresses.
Ludwig H; Avet-Loiseau H; Bladé J; Boccadoro M; Cavenagh J; Cavo M; Davies F; de la Rubia J; Delimpasi S; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Hess U; Mellqvist UH; Moreau P; San-Miguel J; Sondergeld P; Sonneveld P; Udvardy M; Palumbo A
Oncologist; 2012; 17(5):592-606. PubMed ID: 22573721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
